
    
      This study is planned as prospective randomized, controlled, double-blind study.

      Patients will undergo resection or biopsy of glioblastoma (newly diagnosed glioblastoma),
      will randomization ratio of 1: 1 by the pharmacist (by age,Karnofsky score, extent of tumor
      resection), for two research groups:

      Group number 1 will include 50 patients, who will receive Escitalopram or Placebo at a dose
      of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months. . The dose
      study is fixed and is not aimed at symptomatic treatment of anti-depressant (such as major
      depression).
    
  